BIOMAT Database Logo BIOMAT Database Logo

Montelukast sodium in cystic fibrosis. 2001

A H Morice, and J A Kastelik, and I Aziz

UI MeSH Term Description Entries
D008297 Male Males
D011804 Quinolines
D003521 Cyclopropanes Three-carbon cycloparaffin cyclopropane (the structural formula (CH2)3) and its derivatives.
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000085 Acetates Derivatives of ACETIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxymethane structure. Acetate,Acetic Acid Esters,Acetic Acids,Acids, Acetic,Esters, Acetic Acid
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas

Related Publications

A H Morice, and J A Kastelik, and I Aziz
Montelukast pharmacokinetics in cystic fibrosis.
January 2003, The Journal of pediatrics,
A H Morice, and J A Kastelik, and I Aziz
Effects of long-term treatment with montelukast in mild cystic fibrosis (long term treatment with montelukast in cystic fibrosis).
March 2007, Respiratory medicine,
A H Morice, and J A Kastelik, and I Aziz
Anti-inflammatory effects of montelukast in mild cystic fibrosis.
December 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
A H Morice, and J A Kastelik, and I Aziz
Sodium transport in cystic fibrosis fibroblasts.
April 1981, The New England journal of medicine,
A H Morice, and J A Kastelik, and I Aziz
Sodium channels and cystic fibrosis.
November 2007, Chest,
A H Morice, and J A Kastelik, and I Aziz
Cefsulodin sodium therapy in cystic fibrosis patients.
January 1984, Antimicrobial agents and chemotherapy,
A H Morice, and J A Kastelik, and I Aziz
Sodium chloride deficiency in cystic fibrosis patients.
November 1994, European journal of pediatrics,
A H Morice, and J A Kastelik, and I Aziz
High breast-milk sodium in cystic fibrosis.
December 1977, Lancet (London, England),
A H Morice, and J A Kastelik, and I Aziz
Sodium/glucose cotransporter activity in cystic fibrosis.
August 1996, Archives of disease in childhood,
A H Morice, and J A Kastelik, and I Aziz
Erythrocyte sodium-potassium transport in cystic fibrosis.
May 1992, Pediatric research,
Copied contents to your clipboard!